[Bone-targeted treatment in prostate cancer].

Abstract

Prostate cancer is one of the most common cancers in men. In case of metastatic disease, bone manifestation is presented in 85-90% of the patients. The new targeted treatments are the denosumab RANK-ligand monoclonal antibody and Ra-223-chloride radioisotope therapy. This paper summarizes the treatment possibilities of bone metastasis and presents the results of phase III trials of denosumab and Ra-223-chloride. The upcoming change in financial support underlines the actuality of this paper.

• Authors: Lajos Géczi, István Sinkovics
• Journal: Magyar onkologia (Magy Onkol) Vol. 58 Issue 3 Pg. 199-203 (Sep 2014) ISSN: 0025-0244 [Print] Hungary
• Vernacular Title: Csontáttétek célzott kezelése prosztatarákban.
• PMID: 25260084 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Biomarkers, Tumor
• RANK Ligand
• Radioisotopes
• Denosumab
• Alkaline Phosphatase
• Prostate-Specific Antigen
• radium Ra 223 dichloride
• Radium

Topics

• Alkaline Phosphatase (blood)
• Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Biomarkers, Tumor (blood)
• Bone Neoplasms (drug therapy, secondary)
• Clinical Trials, Phase III as Topic
• Denosumab
• Humans
• Male
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (drug therapy, pathology)
• RANK Ligand (antagonists & inhibitors)
• Radioisotopes (pharmacology, therapeutic use)
• Radium (pharmacology, therapeutic use)
• Randomized Controlled Trials as Topic
• Treatment Outcome